Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status approved
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 63629-5688; 49452-7523; 59116-0631; 0093-3234; 70518-0185; 51552-1044; 51927-0081; 50090-2013; 59762-5000; 62135-960; 70518-1829; 70518-3732; 0013-0102; 71610-577; 62705-0222; 62991-2704; 59762-0104; 70518-2342; 71610-706; 49964-0018; 57294-021; 50090-0086; 51927-0054; 59116-0632; 0591-0796; 23155-019; 0013-0101; 63629-9715; 38779-0176; 59116-0630; 59116-0633; 68022-7065
UNII 3XC8GUZ6CB
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pruritus23.03.12.001--
Pseudomembranous colitis07.19.01.003; 11.02.02.002--Not Available
Psoriasis23.03.14.002; 10.02.01.036--Not Available
Psoriatic arthropathy23.03.14.005; 15.01.10.001; 10.02.01.0310.001364%Not Available
Pulmonary eosinophilia01.02.04.006; 22.01.01.0090.000455%Not Available
Pulmonary fibrosis22.01.02.0060.001061%
Pulmonary granuloma22.01.01.0140.000303%Not Available
Pulmonary oedema22.01.03.003; 02.05.02.003--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pustular psoriasis23.03.14.006; 10.02.01.1020.000303%Not Available
Pyrexia08.05.02.0030.011578%
Rash23.03.13.0010.050827%Not Available
Rash erythematous23.03.13.0290.001515%Not Available
Rash macular23.03.13.0030.000606%Not Available
Rash maculo-papular23.03.13.0040.001667%
Rash morbilliform23.03.13.0050.000455%Not Available
Raynaud's phenomenon24.04.03.0030.000303%Not Available
Renal cyst20.01.04.001; 16.27.01.0010.000303%Not Available
Retching07.01.07.0020.001182%Not Available
Rhabdomyolysis15.05.05.002--
Rheumatoid arthritis15.01.03.001; 10.04.06.0010.003637%Not Available
Rosacea23.02.08.001--Not Available
Seizure17.12.03.001--
Serum sickness12.02.08.004; 10.01.03.004--
Shock24.06.02.0020.000606%Not Available
Sinus congestion22.04.06.001--Not Available
Sinus tachycardia02.03.03.0100.000606%
Sjogren's syndrome15.06.01.015; 10.04.04.009; 07.06.01.010; 06.08.02.0110.000303%Not Available
Skin discolouration23.03.03.0050.000970%Not Available
Skin disorder23.03.03.007--Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene